A post-hoc analysis of the ESSENCE 1 trial revealed that 0.1% cyclosporine solution in a semifluorinated alkane vehicle effectively treats moderate dry eye disease.

Kymera Therapeutics initiates Phase 1 clinical trial for KT-621, a first-in-class oral STAT6 degrader, marking the first STAT6-targeted medicine in clinical development.

The Data Monitoring Committee (DMC) recommended continuation of Inventiva's NATiV3 Phase 3 trial for MASH without protocol modification.

Lipella Pharmaceuticals completes the first cohort dosing in its Phase 2a trial of LP-310 for Oral Lichen Planus (OLP).

A study is underway to evaluate a structured, multidisciplinary long-term care program for pediatric cancer survivors, focusing on improving self-efficacy and overall well-being.

Barinthus Bio has commenced a Phase 1 clinical trial for VTP-1000, an investigational immunotherapy for celiac disease, a condition affecting approximately one in 100 people globally.

Leading experts establish new framework "If they RECUR, you should refer" to promote early patient referral for CAR T-cell therapy in large B-cell lymphoma patients.

A comprehensive US-based PRIDE study of 4,426 sexual and gender minority adults reveals significant associations between conversion practices and adverse mental health outcomes.

Cancer Research UK (CRUK) has received a US$225 million investment to enhance cancer research and treatment, focusing on personalized medicine and early detection.

Scientists at Wroclaw University of Technology have received a €1.2 million grant from the National Science Centre to develop innovative antibody-drug conjugates for Alzheimer's disease treatment.

A groundbreaking drug Qalsody, targeting the SOD-1 gene mutation, demonstrates first-ever improvements in some genetic ALS patients, marking a significant advancement in treatment.

Restore Vision Inc. has initiated the world's first clinical trial of optogenetic gene therapy using "Chimeric Rhodopsin" technology for treating retinitis pigmentosa patients.

New research from the University of Granada shows significant overlap between cluster headache, fibromyalgia, and migraine, with 57.1% of cluster headache patients experiencing at least one comorbid condition.

Neuropeutics Inc has been named the first recipient of the AbbVie Biotech Innovators Award for developing small molecules that prevent and reverse protein aggregation in neurodegenerative diseases.

Oxford University researchers have conducted a comprehensive review examining the potential benefits of GLP-1 receptor agonists like semaglutide in treating various mental health conditions.

University of Cambridge researchers have discovered that aspirin enhances the immune system's ability to recognize and destroy metastasizing cancer cells through T-cell activation.

Infex Therapeutics and Justus-Liebig-University Giessen secure £1M PACE grant to develop first-in-class BamA inhibitor targeting multi-drug resistant Gram-negative pathogens.

Scenic Biotech and Stanford University researchers have identified PLA2G15 as a promising therapeutic target for neurometabolic disorders, publishing their findings in Nature.

BlinkLab has launched a significant FDA registrational study for its Dx 1 platform, designed to aid in autism diagnosis. The study plans to recruit up to 1,100 children across multiple U.S. sites, with final results expected by the end of 2025 to support 510(k) FDA approval. The company has also partnered with Monash University for the MAGNET study to enhance its diagnostic capabilities for autism and ADHD.

A groundbreaking non-toxic bacterial therapy, BacID, developed by a University of Massachusetts Amherst-Ernest Pharmaceuticals team, is set to enter clinical trials by 2027. This innovative treatment aims to deliver cancer-fighting drugs directly into tumors, offering a safer and more effective alternative to traditional therapies like chemotherapy. The technology leverages genetically engineered Salmonella strains to target tumors precisely, minimizing damage to healthy tissues and maximizing therapeutic impact.